|
Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry.
|
Bons JA, de Boer D, van Dieijen-Visser MP, Wodzig WK
|
16332361
|
01-04-2006
|
17-04-2026
|
|
|
Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients.
|
Vanschoonbeek K, Thomassen BJ, Senden JM, Wodzig WK, van Loon LJ
|
16549460
|
01-04-2006
|
17-04-2026
|
|
|
Interpretation of cardiac troponin T behaviour in size-exclusion chromatography.
|
Michielsen EC, Diris JH, Kleijnen VW, Wodzig WK, Van Dieijen-Visser MP
|
17163817
|
01-01-2006
|
17-04-2026
|
|
|
Inadequate attempts to measure the microheterogeneity of transthyretin by low-resolution mass spectrometry.
|
de Boer D, Erps MM, Wodzig WK, van Dieijen-Visser MP
|
15976117
|
01-07-2005
|
17-04-2026
|
|
|
Highly sensitive immunoprecipitation method for extracting and concentrating low-abundance proteins from human serum.
|
Michielsen EC, Diris JH, Hackeng CM, Wodzig WK, Van Dieijen-Visser MP
|
15613717
|
01-01-2005
|
17-04-2026
|
|
|
Protein profiling as a diagnostic tool in clinical chemistry: a review.
|
Bons JA, Wodzig WK, van Dieijen-Visser MP
|
16309363
|
01-01-2005
|
17-04-2026
|
|
|
Reference values for N-terminal pro-B-type natriuretic peptide in umbilical cord blood.
|
Bakker J, Gies I, Slavenburg B, Bekers O, Delhaas T, van Dieijen-Visser M
|
15563504
|
01-12-2004
|
25-04-2026
|
|
|
Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects.
|
Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ
|
15363639
|
01-10-2004
|
25-04-2026
|
|
|
Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder.
|
Wu X, Steet RA, Bohorov O, Bakker J, Newell J, Krieger M, Spaapen L, Kornfeld S, Freeze HH
|
15107842
|
01-05-2004
|
25-04-2026
|
|
|
The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure.
|
van Kimmenade RR, Bakker JA, Crijns HJ, van Dieijen-Visser MP, Pinto YM
|
25696296
|
01-02-2004
|
25-04-2026
|
|
|
Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates.
|
de Groot MJ, Wodzig KW, Simoons ML, Glatz JF, Hermens WT
|
10690308
|
01-11-1999
|
17-04-2026
|
|
|
Thrombolytic therapy does not change the release ratios of enzymatic and non-enzymatic myocardial marker proteins.
|
Wodzig KW, Kragten JA, Modrzejewski W, Górski J, van Dieijen-Visser MP, Glatz JF, Hermens WT
|
9641361
|
27-04-1998
|
17-04-2026
|
|
|
One-step enzyme-linked immunosorbent assay (ELISA) for plasma fatty acid-binding protein.
|
Wodzig KW, Pelsers MM, van der Vusse GJ, Roos W, Glatz JF
|
9158823
|
01-05-1997
|
17-04-2026
|
|
|
Estimation of myocardial infarct size from plasma myoglobin or fatty acid-binding protein. Influence of renal function.
|
Wodzig KW, Kragten JA, Hermens WT, Glatz JF, van Dieijen-Visser MP
|
9127740
|
01-03-1997
|
17-04-2026
|
|
|
Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein.
|
Van Nieuwenhoven FA, Kleine AH, Wodzig WH, Hermens WT, Kragten HA, Maessen JG, Punt CD, Van Dieijen MP, Van der Vusse GJ, Glatz JF
|
7586251
|
15-11-1995
|
17-04-2026
|
|
|
Monoclonal antibodies to human heart fatty acid-binding protein.
|
Roos W, Eymann E, Symannek M, Duppenthaler J, Wodzig KW, Pelsers M, Glatz JF
|
7541428
|
14-06-1995
|
17-04-2026
|
|
